Want to join the conversation?
$ABBV said it launched VENCLEXTA early in 2Q16 in its initial indication for relapsed/refractory CLL patients with a 17p deletion, which represents a smaller addressable patient population in the US. The company has begun a measured commercial rollout to ensure adequate physician training and expects a modest level of VENCLEXTA sales for 2016.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.